$8.23
2.72% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

ITeos Therapeutics Inc Stock price

$8.23
-1.19 12.63% 1M
-9.73 54.18% 6M
-2.72 24.84% YTD
-1.84 18.27% 1Y
-22.17 72.93% 3Y
-10.82 56.80% 5Y
-10.82 56.80% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.23 2.72%
ISIN
US46565G1040
Symbol
ITOS
Sector
Industry

Key metrics

Market capitalization $300.67m
Enterprise Value $-182.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.52
EV/Sales (TTM) EV/Sales -5.21
P/S ratio (TTM) P/S ratio 8.59
P/B ratio (TTM) P/B ratio 0.48
Revenue growth (TTM) Revenue growth -47.37%
Revenue (TTM) Revenue $35.00m
EBIT (operating result TTM) EBIT $-150.34m
Free Cash Flow (TTM) Free Cash Flow $-120.32m
Cash position $488.71m
EPS (TTM) EPS $-3.15
P/E forward negative
P/S forward 8.83
EV/Sales forward negative
Short interest 19.62%
Show more

Is ITeos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

ITeos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ITeos Therapeutics Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a ITeos Therapeutics Inc forecast:

Buy
100%

Financial data from ITeos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
35 35
47% 47%
100%
- Direct Costs 1.15 1.15
32% 32%
3%
34 34
48% 48%
97%
- Selling and Administrative Expenses 48 48
1% 1%
138%
- Research and Development Expense 135 135
22% 22%
385%
-149 -149
61% 61%
-426%
- Depreciation and Amortization 1.15 1.15
32% 32%
3%
EBIT (Operating Income) EBIT -150 -150
61% 61%
-430%
Net Profit -121 -121
97% 97%
-346%

In millions USD.

Don't miss a Thing! We will send you all news about ITeos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ITeos Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
- EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $6...
Negative
Investors Business Daily
2 months ago
Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.
Positive
Seeking Alpha
2 months ago
iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to surviv...
More ITeos Therapeutics Inc News

Company Profile

iTeos Therapeutics, Inc. engages in the development of biopharmaceuticals therapeutic products and services. It offers immuno-oncology therapeutics for patients. The company was founded by Michel Detheux in April 2012 and is headquartered in Cambridge, MA.

Head office United States
CEO Michel Detheux
Employees 157
Founded 2012
Website www.iteostherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today